Nonetheless, the ability of langerin+ DCs to induce antigen-specific Foxp3+ Tregs in lungs, suggest that anti-langerin mAbs is an attractive candidate for the treatment of respiratory dysregulated immune responses like allergies (Figure 2). This evidence concerns the gene CD207 and allergic disease.